Skip to main content

Knee Arthroplasty, Total

1
Pipeline Programs
6
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
1
EnoxaparinPhase 21 trial
Active Trials
NCT03276143Completed813Est. Jan 2019
Exactech
ExactechFL - Gainesville
4 programs
Optetrak Logic CR Knee SystemN/A1 trial
Optetrak Total Knee SystemN/A1 trial
Prospective / Subjects Knee ArthroplastyN/A1 trial
Truliant Total Knee SystemN/A1 trial
Active Trials
NCT05516381Recruiting148Est. Jun 2027
NCT05788757Active Not Recruiting4,588Est. Jun 2034
NCT07107581Enrolling By Invitation1,879Est. Jan 2036
+1 more trials
Abbott
AbbottABBOTT PARK, IL
1 program
Genicular Nerve RFAN/A1 trial
Active Trials
NCT02947321Completed60Est. Sep 2020
Stryker
StrykerCA - San Jose
1 program
Group primary TKAN/A
Nordic Pharma
Nordic PharmaFrance - Paris
1 program
Group primary TKAN/A1 trial
Active Trials
NCT03898544Completed32Est. Sep 2020
Zimmer Biomet
Zimmer BiometFL - Jacksonville
1 program
Total Knee ArthroplastyN/A1 trial
Active Trials
NCT07009912Completed40Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BayerEnoxaparin
Zimmer BiometTotal Knee Arthroplasty
ExactechProspective / Subjects Knee Arthroplasty
ExactechOptetrak Logic CR Knee System
Nordic PharmaGroup primary TKA
ExactechTruliant Total Knee System
AbbottGenicular Nerve RFA
ExactechOptetrak Total Knee System

Clinical Trials (8)

Total enrollment: 8,560 patients across 8 trials

NCT03276143BayerEnoxaparin

FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Start: Sep 2017Est. completion: Jan 2019813 patients
Phase 2Completed
NCT07009912Zimmer BiometTotal Knee Arthroplasty

ROSA® Knee System V1.5 Pilot Study

Start: Feb 2025Est. completion: Feb 202640 patients
N/ACompleted
NCT07107581ExactechProspective / Subjects Knee Arthroplasty

Exactech Knee Systems Post Market Clinical Follow-up

Start: Dec 2023Est. completion: Jan 20361,879 patients
N/AEnrolling By Invitation
NCT05516381ExactechOptetrak Logic CR Knee System

Evaluation of Navigation-Assisted TKA Using Mechanical vs. Restricted Kinematic Alignment

Start: May 2023Est. completion: Jun 2027148 patients
N/ARecruiting
NCT03898544Nordic PharmaGroup primary TKA

Gait Kinematics After Primary Total Knee Arthroplasty (TKA) Versus Revision TKA

Start: Mar 2019Est. completion: Sep 202032 patients
N/ACompleted
NCT05653102ExactechTruliant Total Knee System

A Post-Market Domestic (US) and International Data Collection to Assess the Truliant Knee System

Start: Jan 2019Est. completion: Jul 20351,000 patients
N/ARecruiting
NCT02947321AbbottGenicular Nerve RFA

Genicular Radiofrequency Ablation Efficacy in Achieving Total Knee Pain Reduction Trial

Start: Jan 2018Est. completion: Sep 202060 patients
N/ACompleted
NCT05788757ExactechOptetrak Total Knee System

Optetrak Knee System Post Market Clinical Follow-Up

Start: Jun 2011Est. completion: Jun 20344,588 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 8,560 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.